ACRX Acelrx Pharmaceuticals Inc

Price (delayed)

$0.18

Market cap

$26.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$21.27M

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers ...

Highlights
ACRX's EPS is up by 23% year-on-year and by 7% since the previous quarter
ACRX's gross profit is up by 20% QoQ
ACRX's revenue has shrunk by 50% YoY and by 2.4% QoQ
The quick ratio has declined by 47% year-on-year and by 17% since the previous quarter

Key stats

What are the main financial stats of ACRX
Market
Shares outstanding
147.11M
Market cap
$26.48M
Enterprise value
$21.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
9.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.74
Earnings
Revenue
$2.75M
EBIT
-$32.79M
EBITDA
-$30.84M
Free cash flow
-$31.12M
Per share
EPS
-$0.27
Free cash flow per share
-$0.21
Book value per share
-$0.26
Revenue per share
$0.02
TBVPS
$0.49
Balance sheet
Total assets
$71.97M
Total liabilities
$110.24M
Debt
$16.62M
Equity
-$38.27M
Working capital
$25.78M
Liquidity
Debt to equity
-0.43
Current ratio
2.51
Quick ratio
2.32
Net debt/EBITDA
0.17
Margins
EBITDA margin
-1,122%
Gross margin
-27.2%
Net margin
-1,266.5%
Operating margin
-1,302.9%
Efficiency
Return on assets
-46.2%
Return on equity
N/A
Return on invested capital
-55.1%
Return on capital employed
-59.7%
Return on sales
-1,192.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRX stock price

How has the Acelrx Pharmaceuticals stock price performed over time
Intraday
-9.73%
1 week
-15.09%
1 month
-19.25%
1 year
-86.86%
YTD
-67.87%
QTD
-36.95%

Financial performance

How have Acelrx Pharmaceuticals's revenue and profit performed over time
Revenue
$2.75M
Gross profit
-$748,000
Operating income
-$35.82M
Net income
-$34.82M
Gross margin
-27.2%
Net margin
-1,266.5%
ACRX's operating margin has shrunk by 111% YoY and by 2.1% QoQ
Acelrx Pharmaceuticals's net margin has plunged by 110% YoY
ACRX's revenue has shrunk by 50% YoY and by 2.4% QoQ
ACRX's gross profit is up by 20% QoQ

Growth

What is Acelrx Pharmaceuticals's growth rate over time

Valuation

What is Acelrx Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
9.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.74
ACRX's EPS is up by 23% year-on-year and by 7% since the previous quarter
ACRX's equity is down by 40% YoY and by 7% from the previous quarter
ACRX's price to sales (P/S) is 79% lower than its 5-year quarterly average of 45.2 and 70% lower than its last 4 quarters average of 31.7
ACRX's revenue has shrunk by 50% YoY and by 2.4% QoQ

Efficiency

How efficient is Acelrx Pharmaceuticals business performance
ACRX's return on sales has dropped by 116% year-on-year and by 2.5% since the previous quarter
ACRX's ROA is down by 4.3% since the previous quarter
The company's return on invested capital fell by 3.4% QoQ

Dividends

What is ACRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRX.

Financial health

How did Acelrx Pharmaceuticals financials performed over time
Acelrx Pharmaceuticals's total assets is 35% lower than its total liabilities
The quick ratio has declined by 47% year-on-year and by 17% since the previous quarter
The company's current ratio fell by 45% YoY and by 16% QoQ
Acelrx Pharmaceuticals's debt is 143% more than its equity
The debt to equity has grown by 43% YoY and by 17% from the previous quarter
ACRX's equity is down by 40% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.